Laboratoires Squibb

Bristol Myers Squibb (BMS) is a leading global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines for serious diseases. The company maintains a dominant position in oncology, hematology, immunology, and cardiovascular health, supported by a portfolio of blockbuster treatments such as Opdivo and Eliquis. BMS has significantly expanded its capabilities in cell therapy and precision medicine through strategic acquisitions, including the multi-billion dollar purchase of Celgene. With a robust clinical pipeline and a strong international presence, including its historical French operations known as Laboratoires Squibb, the company continues to drive advancements in therapeutic areas with high unmet medical needs. BMS is committed to scientific excellence and patient-centric innovation to improve health outcomes worldwide.